Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum

9/8/25 4:25:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $JNJ alert in real time by email

Johnson & Johnson (NYSE:JNJ) will present at the Bernstein 2^nd Annual Healthcare Forum on Wednesday, September 24^th, 2025. Management will participate in a Fireside Chat at 1:10 p.m. Eastern Time.

A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day.

The audio webcast replay will be available approximately 48 hours after the webcast.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250908878054/en/

Media contact:

[email protected]

Investor contact:

[email protected]

Get the next $JNJ alert in real time by email

Crush Q3 2025 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$JNJ

Date	Price Target	Rating	Analyst
7/23/2025		Hold → Buy	Erste Group
5/13/2025	$153.00	Outperform → Market Perform	Leerink Partners
12/10/2024	$166.00	Neutral	BofA Securities
11/15/2024	$190.00	Outperform	Wolfe Research
7/23/2024	$160.00 → $150.00	Outperform → Neutral	Daiwa Securities
5/30/2024	$160.00	Neutral	Goldman
4/18/2024	$170.00	Hold → Buy	HSBC Securities
12/13/2023	$170.00 → $163.00	Overweight → Equal Weight	Wells Fargo

More analyst ratings

$JNJ
Press Releases

Fastest customizable press release news feed in the world

View All

Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

9/8/25 6:17:00 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum

Johnson & Johnson (NYSE:JNJ) will present at the Bernstein 2nd Annual Healthcare Forum on Wednesday, September 24th, 2025. Management will participate in a Fireside Chat at 1:10 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20250908878054/en/ Media contact: [email protected] Investor contact: [email protected]

9/8/25 4:25:00 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer

Chemotherapy-free combination regimen ushers in new era for first-line treatment, with overall survival projected to exceed four years, surpassing monotherapy TKI osimertinib by more than one year RARITAN, N.J., Sept. 7, 2025 /PR Newswire/ – Johnson & Johnson (NYSE: JNJ) today announced The New England Journal of Medicine (NEJM) published results from the Phase 3 MARIPOSA study, which showed RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival (OS) improvement for patients with previously

9/7/25 3:22:00 AM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

$JNJ
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

View All

July 21, 2023 - FDA Roundup: July 21, 2023

For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

7/21/23 4:02:23 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

5/5/22 4:51:11 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

8/18/21 1:06:11 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

$JNJ
Leadership Updates

Live Leadership Updates

View All

Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

9/8/25 6:17:00 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

6/10/25 4:51:00 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines

3/25/25 1:11:06 PM ET

$JNJ

$TVGN

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

$JNJ
Financials

Live finance-specific insights

View All

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 14th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay o

9/3/25 4:29:00 PM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on September 9, 2025 to shareholders of record at the close of business on August 26, 2025. The ex-dividend date is August 26, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely po

7/16/25 6:25:00 AM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* 2025 Second-Quarter reflects earnings per share (EPS) of $2.29 and adjusted EPS of $2.77 Significant new product pipeline progress including approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, data for CARVYKTI overall survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA Strong operational performance and favorable foreign exchange results in Company increasing full year estimated reported sales5 guidance at the midpoint b

7/16/25 6:20:00 AM ET

$JNJ

Biotechnology: Pharmaceutical Preparations

Health Care

Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$JNJ

Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$JNJ

$JNJ
Analyst Ratings

Johnson & Johnson upgraded by Erste Group

Johnson & Johnson downgraded by Leerink Partners with a new price target

BofA Securities resumed coverage on Johnson & Johnson with a new price target

$JNJ
Press Releases

Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum

Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer

$JNJ
Insider Purchases

Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

$JNJ
SEC Filings

Johnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

SEC Form 144 filed by Johnson & Johnson

SEC Form N-PX filed by Johnson & Johnson

$JNJ
Insider Trading

EVP, WWC. Innovative Medicine Taubert Jennifer L exercised 56,471 shares at a strike of $101.87 and sold $10,040,883 worth of shares (56,471 units at $177.81) (SEC Form 4)

Executive VP, General Counsel Forminard Elizabeth exercised 11,521 shares at a strike of $115.67 and covered exercise/tax liability with 9,570 shares, increasing direct ownership by 18% to 12,853 units (SEC Form 4)

CEO and Chairman of the Board Duato Joaquin exercised 125,824 shares at a strike of $101.87 and sold $22,548,655 worth of shares (125,824 units at $179.21) (SEC Form 4)

$JNJ
FDA approvals

July 21, 2023 - FDA Roundup: July 21, 2023

May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

$JNJ
Leadership Updates

Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

$JNJ
Financials

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

$JNJ
Large Ownership Changes

SEC Form SC 13G filed by Johnson & Johnson

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $JNJ

Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for $JNJ

$JNJ Analyst Ratings

Johnson & Johnson upgraded by Erste Group

Johnson & Johnson downgraded by Leerink Partners with a new price target

BofA Securities resumed coverage on Johnson & Johnson with a new price target

$JNJ Press Releases

Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

Johnson & Johnson to Participate in the Bernstein 2nd Annual Healthcare Forum

Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer

$JNJ Insider Purchases

Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

$JNJ SEC Filings

Johnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

SEC Form 144 filed by Johnson & Johnson

SEC Form N-PX filed by Johnson & Johnson

$JNJ Insider Trading

EVP, WWC. Innovative Medicine Taubert Jennifer L exercised 56,471 shares at a strike of $101.87 and sold $10,040,883 worth of shares (56,471 units at $177.81) (SEC Form 4)

Executive VP, General Counsel Forminard Elizabeth exercised 11,521 shares at a strike of $115.67 and covered exercise/tax liability with 9,570 shares, increasing direct ownership by 18% to 12,853 units (SEC Form 4)

CEO and Chairman of the Board Duato Joaquin exercised 125,824 shares at a strike of $101.87 and sold $22,548,655 worth of shares (125,824 units at $179.21) (SEC Form 4)

$JNJ FDA approvals

July 21, 2023 - FDA Roundup: July 21, 2023

May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

$JNJ Leadership Updates

Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

$JNJ Financials

Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

$JNJ Large Ownership Changes

SEC Form SC 13G filed by Johnson & Johnson

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

Recent Analyst Ratings for
$JNJ

Recent Analyst Ratings for
$JNJ

$JNJ
Analyst Ratings

$JNJ
Press Releases

$JNJ
Insider Purchases

$JNJ
SEC Filings

$JNJ
Insider Trading

$JNJ
FDA approvals

$JNJ
Leadership Updates

$JNJ
Financials

$JNJ
Large Ownership Changes